**Core Concept**
Erlotinib is a targeted therapy drug used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, thereby blocking the signal transduction pathway that promotes cancer cell growth.

**Why the Correct Answer is Right**
Erlotinib is a small molecule tyrosine kinase inhibitor that specifically targets the EGFR tyrosine kinase domain. It binds to the ATP-binding site of EGFR, preventing the phosphorylation and activation of downstream signaling pathways. However, the absorption of erlotinib is significantly increased by food, particularly fatty meals, which can lead to increased bioavailability and potentially severe adverse effects. This is in contrast to most other oral medications, where food can decrease absorption.

**Why Each Wrong Option is Incorrect**
**Option A:** Erlotinib is indeed used in the treatment of non-small cell carcinoma of the lung, particularly in patients with EGFR mutations. It has shown significant efficacy in clinical trials and is a standard treatment option for this patient population.

**Option B:** Erlotinib is a small molecule tyrosine kinase inhibitor that acts as an EGFR antagonist, which is correct. It specifically targets the EGFR tyrosine kinase domain and inhibits its activity, leading to the inhibition of cancer cell growth and proliferation.

**Option D:** Erlotinib can cause skin rashes and diarrhea as common adverse effects, which is correct. These adverse effects are often dose-limiting and can impact patient quality of life.

**Clinical Pearl / High-Yield Fact**
When prescribing erlotinib, it's essential to advise patients to take the medication on an empty stomach, at least 1 hour before or 2 hours after a meal. This can help minimize the risk of severe adverse effects and optimize treatment outcomes.

**✓ Correct Answer: C. Food decreases absorption**